Sleep reactivity to stress and insomnia: sleep measures and molecular markers

Objective. To identify objective measures of sleep and molecular markers of sleep reactivity to stress to determine its role for insomnia prevention and management. Design and methods. The sample included 42 subjects with sleep disturbances and 23 subjects without sleep-related complaints (control group) aged 18 to 72 years. Altogether there are 19 men and 55 women. Nine participants were excluded from the study. Sleep reactivity to stress was assessed using the Ford Insomnia Response to Stress Test (FIRST) questionnaire. The Integrative Anxiety Test was used to screen for anxiety. Sleep indices were assessed by polysomnography (PSG). Blood plasma samples were collected in the morning after PSG to determine brain-derived neurotrophic factor (BDNF), and 24-hour urine was collected one week after PSG to assess metanephrine levels. Results. There were 64 % healthy subjects with low sleep reactivity to stress and low anxiety and 79 % subjects showed insomnia among persons with high sleep reactivity and anxiety. Significant differences in PSG measures were found in groups with low and high sleep reactivity: the efficiency of sleep and the percentage of the second stage of NREM sleep were higher in group with low reactivity, also sleep latency and wake time after sleep onset were lower in group with high reactivity. In addition, serum BDNF level was significantly higher in group with low reactivity, and it correlates positively with daily urinary metanephrine excretion and the absolute duration of stage N3 and negatively with sleep latency. Conclusions. Subjects with high reactivity to stress have lower sleep quality and depth that corresponds to other studies. The level of BDNF is a possible marker of sleep reactivity to stress and it can indicate the potential adaptation to stress.

1. Morin CM, Carrier J. The acute effects of the COVID-19 pandemic on insomnia and psychological symptoms. Sleep Med. 2021;77:346-347. doi: 10.1016Zj.sleep.2020.06.005.

2. Dopheide JA. Insomnia overview: epidemiology, pathophysiology, diagnosis and monitoring, and nonpharmacologic therapy. Am J Manag Care. 2020;26(4 Suppl):S76-S84. doi: 10.37765/ajmc.2020.42769.

3. Sateia MJ. International classification of sleep disorders-third edition: highlights and modifications. Chest. 2014;146(5):1387–1394. doi:10.1378/chest.14-0970

4. Lin L, Wang J, Ouyang X. The immediate impact of the 2019 novel coronavirus (COVID-19) outbreak on subjective sleep status. Sleep Med. 2020;77:54–348.

5. Drake CL, Pillai V, Roth T. Stress and sleep reactivity: A prospective investigation of the stress-diathesis model of insomnia. Sleep. 2013;37(8):1295–1304.

6. Poluektov MG, Pchelina PV. Chronic insomnia: treatment methods based on the current “3P” model of insomnia. S.S. Korsakov Journal of Neurology and Psychiatry = Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova. 2015;115(12):141-147. doi: 10.17116/jnevro2015115112141-147. In Russian

7. Holsboer F, Ising M. Stress hormone regulation: biological role and translation into therapy. Annu Rev Psychol. 2010;61:81–109. doi: 10.1146/annurev.psych.093008.100321.

8. Miller GE, Chen E, Zhou ES. If it goes up, must it come down? Chronic stress and the hypothalamic-pituitary-adrenocortical axis in humans. Psychol Bull. 2007;133:25–45.

9. Riemann D, Spiegelhalder K, Feige B, Voderholzer U, Berger M, Perlis M et al. The hyperarousal model of insomnia: A review of the concept and its evidence. Sleep Medicine Reviews. 2010;14(1):19–31. doi: 10.1016/j.smrv.2009.04.002

10. Grimaldi D, Reid KJ, Papalambros NA, Braun RI, Malkani RG, Abbott SM et al. Autonomic dysregulation and sleep homeostasis in insomnia. Sleep. 2021;44(6): zsaa274. doi:10.1093/sleep/zsaa274

11. Smith MA, Makino S, Kvetnansky R, Post RM. Stress and glucocorticoids affect the expression of brain-derived neurotrophic factor and neurotrophin-3 mRNAs in the hippocampus. J Neurosci. 1995;15(3 Pt 1):1768–77.

12. Nibuya M, Morinobu S, Duman RS. Regulation of BDNF and trkB mRNA in rat brain by chronic electroconvulsive seizure and antidepressant drug treatments. J Neurosci. 1995;15:7539–47.

13. Lakshminarasimhan H, Chattarji S. Stress leads to contrasting effects on the levels of brain derived neurotrophic factor in the hippocampus and amygdala. PLoS One. 2012;7:e30481.

14. Giese M, Unternährer E, Hüttig H, Beck J, Brand S, Calabrese P et al. BDNF: an indicator of insomnia?. Mol Psychiatry. 2014;19(2): 151–152. doi: 10.1038/mp.2013.10

15. Giese M, Unternaehrer E, Brand S, Calabrese P, Holsboer-Trachsler E, Eckert A. The Interplay of Stress and Sleep Impacts BDNF Level. PLoS ONE. 2013;8(10): e76050. https://doi.org/10.1371/journal.pone.0076050

16. Berry RB, Brooks R, Gamaldo CE, Harding SM, Marcus CL, Vaughn BV. The AASM Manual for the Scoring of Sleep and Associated Events: Rules, Terminology and Technical Specifications, Version 2.5. Darien, IL: American Academy of Sleep Medicine. 2018.

17. Drake CL, Friedman NP, Wright KP, Roth T. Sleep Reactivity and Insomnia: Genetic and Environmental Influences. Sleep. 2011; 34(9):1179–1188. doi: 10.5665/SLEEP.1234

18. Kalmbach DA, Pillai V, Arnedt JT, Drake CL. Identifying at-risk individuals for insomnia using the Ford Insomnia Response to Stress Test. Sleep. 2016;39(2):449–456.

19. Bizyuk AP, Vasserman LI, Iovlev BV. Application of the integrative anxiety test (IAT): guidelines. St. Petersburg, The St. Petersburg Bekhterev Psychoneurological Research Institute Editorial, 2005. 23 p. (In Russian)

20. Ohayon M, Wickwire EM, Hirshkowitz M, Albert SM, Avidan A, Daly FJ et al. National Sleep Foundation's sleep quality recommendations: first report. Sleep Health. 2017;3(1):6-19. doi: 10.1016/j.sleh.2016.11.006.

21. Bonnet MH, Arand DL. Situational insomnia: Consistency, predictors, and outcomes. Sleep. 2003;26(8):1029–1036.

22. Chen I, Jarrin D, Rochefort A, Lamy M, Ivers H, Morin C. Validation of the French version of the Ford insomnia response to stress test and the association between sleep reactivity and hyperarousal. Sleep Medicine. 2015;16:S238.

23. Bochkarev MV, Kulakova MA, Kemstach VV, Gordeev AD, Zabroda EN, Osipenko SI et al. Sympathoadrenal activity and sleep: in the search for a marker of hyperarousal in insomnia. Arterial’naya Gipertenziya = Arterial Hypertension. 2021;27(5):546–552. In russian

24. Vgontzas AN, Bixler EO, Lin H, Prolo P, Mastorakos G, Vela-Bueno A et al. Chronic insomnia is associated with nyctohemeral activation of the hypothalamic-pituitary-adrenal axis: clinical implications. J Clin Endocrinol Metab. 2001;86(8):3787–3794. doi:10.1210/jcem.86.8.7778

25. Schmitt K, Holsboer-Trachsler E, Eckert A. BDNF in sleep, insomnia, and sleep deprivation, Annals of Medicine. 2016;48(1-2):42-51. DOI: 10.3109/07853890.2015.1131327

26. Dijk DJ. Regulation and functional correlates of slow wave sleep. J Clin Sleep Med. 2009;5(2 Suppl):S6-15.

27. Notaras M, van den Buuse M. Neurobiology of BDNF in fear memory, sensitivity to stress, and stress-related disorders. Mol Psychiatry. 2020: 25(10):2251–2274. doi: 10.1038/s41380-019-0639-2